RE:RE:RE:RE:RE:RE:Concerns over vCJD 'blood threat' - the issue that refuses..Staghorn69,
The deal with GSK is alive and well. Any change to the method of development would mean GSK would have to go back to the beginning and demonstrate equivalency. No, they are tied at the hip. Pierre commented on the lack of transparency regarding public disclosure (on GSK's part), and the frustration it creates, but noted it will show through via revenues.